Orion Biosciences Co-Founder Du Zhengping Confirms Participation in the 2nd International Medical Device Innovation Summit

“To further analyze the innovation, transformation, and development of China’s medical device industry, gain insights into emerging trends, and promote the integration of industry and capital, this event is hosted by the People’s Government of Gaochun District, organized by the Gaochun District Science and Technology Bureau and VCBeat, and co-organized by Jiangsu Gaochun High-Tech Industrial Development Zone.”The 2nd International Summit on Medical Device Innovation"will be held onJuly 28, 2020AtNanjing · GaochunHosted.

Du Zhengping, Co-founder of Aoran Biotech, Confirms Attendance at the 2nd International Summit on Medical Device Innovation.

Du Zhengping，Co-founder of Aoran Biotech

Mr. Zhengping Du, Vice President of Reagent and Application R&D and Co-founder of Aoran Biotechnology. He earned his bachelor’s and master’s degrees in Bioengineering from South China University of Technology. With over 15 years of research and work experience in the field of molecular diagnostics, he possesses extensive expertise in reagent development and regulatory registration. In 2014, he co-founded Aoran Biotechnology and has since served as Vice President of Reagent and Application R&D.

Aoran Biotech, established in 2015 at the Shanghai International Medical Zone, is a high-tech enterprise specializing in molecular diagnostic technologies. With a research and development center located on Guangzhou International Bio Island, the company boasts an R&D and production facility spanning 3,000 square meters. Aoran Biotech has successfully developed a series of fully automated biological analyzers, reagents, and intelligent reagent cassettes for applications in microbial detection, pharmacogenetic testing for personalized medication, cancer screening, forensic evidence analysis, and food safety.

On May 16, 2018, Auragene Biotech officially signed an agreement for a major project under China’s 13th Five-Year Plan. Its Galaxy Nano fully automated qPCR all-in-one system and IGS TB/RIF Lite reagent products will participate in the evaluation. Notably, Auragene Biotech’s independently developed Galaxy Nano and Orion have obtained EU CE certification, while the Universal Nano has received registration as a Class III medical device.

In recent years, as a strategic emerging industry receiving key national support, the medical device sector has enjoyed robust momentum, bolstered by a series of policies ranging from deepened reforms in review and approval processes, innovation in high-value consumables, Diagnosis-Related Groups (DRG), and Supply, Processing, and Distribution (SPD) models, to medical consortiums, tiered diagnosis and treatment systems, and the Marketing Authorization Holder (MAH) system for medical devices. Statistics show that China’s medical device market reached RMB 628.5 billion in 2019, with projections indicating it will exceed RMB 900 billion by 2022.

The 2nd International Summit on Medical Device Innovationwill2020 Medical Device Innovation Vitality Listtaking the release as an opportunity to focus in depth onGenetic Testing, In Vitro Diagnosticsand other hot topics, gathering the most active medical device innovators, listed companies, financial institutions, and healthcare providers from China and abroad to create a medical device industryOfflineGrand Event.

Future Trends: Four 2020 Medical Device Innovation Vitality Lists Released On-Site

Focusing on Four Hot Tracks in the Medical Device Sector: A Curated Selection of Chemiluminescence, Home Medical Equipment, Orthopedic Implants, and Cutting-Edge Tech Products. Who Are the 2020 Enterprises with Innovative Vitality in the Medical Device Industry?At the 2020 Second International Summit on Medical Device Innovation, the 2020 Medical Device Innovation Vitality Rankings will be released. Witness the unveiling of four distinct lists: which 40 companies will emerge as the most innovative?

Featured Guests: Over 18 Leading Experts in the Medical Device Industry Engage in Dialogue with You

Yuan-Ting Zhang, Academician of the International Academy of Medical and Biological Engineering, and Jie Tian, Director of the Key Laboratory of Molecular Imaging of the Chinese Academy of Sciences, will join forces with executives from multinational giant Johnson & Johnson, NMPA medical device review experts, founders of high-quality innovative medical device enterprises, forward-looking medical device investors, and senior department directors to discuss the future of medical devices. More guests are being confirmed; stay tuned.

Partially Confirmed Guests:

Zhang Yuanting, Fellow of the International Academy of Medical and Biological Engineering, IEEE Fellow, and Fellow of the American Institute for Medical and Biological Engineering

Tian Jie, Director of the Key Laboratory of Molecular Imaging, Chinese Academy of Sciences

Bao Ningzhong, Professor at Nanjing Tech University

Dong Yansheng, NMPA Medical Device Review Expert

Wang Jinhe, Vice President of External Affairs and Market Access, Johnson & Johnson (China)

Sun Qi, Founding Managing Partner of DaoTong Capital

Zhao Xiangwei, Deputy Dean of the School of Biological Science and Medical Engineering, Southeast University

Yang Song, Chief Analyst of the Pharmaceutical Industry at Cinda Securities

Wu Hanliang, Director of the Strategy Department at Guotai Junan Securities

Wang Yaqi, Co-founder and Chairman of Raytune Biotech

Du Zhengping, Co-founder of Aoran Biotech    

Zhou Quan, Managing Director at Legend Capital

Qi Hua, Founder of Cenote Bio

Guo Yan, Director of the Pathology Diagnosis Center at Hengdao

Li Gang, Founder of Changjiang Biology

More guests to be confirmed...

In-Depth Content: Two Roundtables Focus on Industry Trends and the Development Direction of In Vitro Diagnostics

In recent years, domestic medical device innovation has surged. The primary market has seen the emergence of unicorn companies such as United Imaging Healthcare, Venus Medtech, and MicroPort CardioFlow. In the secondary market, Mindray Medical’s market capitalization has exceeded RMB 300 billion, while Chunli Medical’s stock price has increased more than tenfold over two years. By segment, China’s in vitro diagnostics (IVD) market reached RMB 60.4 billion in 2018, representing an 18.4% year-on-year growth. It is projected to maintain an annual growth rate of approximately 18%, making China one of the fastest-growing IVD markets globally.

All these signs seem to indicate that the golden age of domestically produced medical devices has arrived. What trends will shape the future development of China’s medical device industry? Which specific segments within the domestic medical device sector hold greater promise for growth? At this summit, the morning roundtable discussion will focus onPost-Pandemic Era Medical DevicesDevelopment opportunities; the afternoon roundtable session will delve into specialized subfields,andSenior Investors in the In Vitro Diagnostics Industry: Precision Dialogues with High-Quality Innovative Enterprises。